CIDP
Clinical trials for CIDP explained in plain language.
Never miss a new study
Get alerted when new CIDP trials appear
Sign up with your email to follow new studies for CIDP, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for steroid-resistant CIDP: blood filtering vs standard therapy
Disease control Recruiting nowThis study tests if a blood-filtering method (immunoadsorption) works better than standard antibody infusions (immunoglobulins) for people with chronic inflammatory demyelinating polyneuropathy (CIDP) who did not improve with steroids. About 20 adults with CIDP for 3 years or les…
Matched conditions: CIDP
Phase: PHASE2 • Sponsor: University of Ulm • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New treatment option opens for CIDP patients who have no other choices
Disease control AVAILABLEThis program provides efgartigimod PH20 SC to adults with CIDP who cannot join a clinical trial and have not been helped by standard treatments like steroids or immunoglobulins. The goal is to control the disease by reducing nerve inflammation. Treatment continues until the patie…
Matched conditions: CIDP
Sponsor: argenx • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug could replace standard IV therapy for nerve disorder
Disease control Recruiting nowThis study tests a new medicine called empasiprubart against the standard treatment (IVIg) for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. About 218 adults who have previously responded to IVIg will re…
Matched conditions: CIDP
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
New study tracks Real-Life impact of CIDP drug on 200 patients
Disease control Recruiting nowThis study follows 200 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are starting treatment with efgartigimod. Researchers will track changes in disability, grip strength, and quality of life over two years to see how well the drug works in real…
Matched conditions: CIDP
Sponsor: argenx • Aim: Disease control
Last updated May 18, 2026 11:58 UTC
-
New CIDP drug trial offers hope for nerve damage relief
Disease control Recruiting nowThis study tests a new drug called empasiprubart for adults with CIDP, a condition that causes nerve damage and weakness. About 160 people will receive either the drug or a placebo for 6 months, then everyone gets the drug for 2 more years. The goal is to see if it improves disab…
Matched conditions: CIDP
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Study explores if body weight changes how immunoglobulin works
Knowledge-focused Recruiting nowThis study looks at how body composition (like weight and muscle) affects the way immunoglobulin G (IgG) is processed in people with CIDP, a nerve disorder. Researchers will give IgG through a vein or under the skin and measure drug levels and half-life. The goal is to improve do…
Matched conditions: CIDP
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated May 18, 2026 12:02 UTC